^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Winrevair (sotatercept-csrk)

    i
    Other names: RAP-011, hActRIIA-IgG1, ActRIIA-IgG1, MK-7962, ACE-011, human ACTRIIA-IgG-Fc, RAP 011
    Associations

    News

    Trials
    Company:
    BMS, Merck (MSD)
    Drug class:
    TGFβ inhibitor
    Related drugs:
    Associations

    News

    Trials
    7d
    Antiproliferative Therapies in Pulmonary Arterial Hypertension. (PubMed, Expert Opin Pharmacother)
    Targeting these pathways, including BMPR2 restoration, TGF-β inhibition, and tyrosine kinase blockade, has shown encouraging results beyond the vasodilator-focused standard of care. These innovations may reshape PAH management by improving outcomes, and potentially altering disease progression.
    Review • Journal
    |
    TGFB1 (Transforming Growth Factor Beta 1)
    |
    Winrevair (sotatercept-csrk)
    7d
    SIRIUS - Initial Combination Therapy With an Endothelin Receptor Antagonist, a Phosphodiesterase-5 Inhibitor and Sotatercept in Patients With Newly Diagnosed Pulmonary Arterial Hypertension (clinicaltrials.gov)
    P2, N=25, Not yet recruiting, Philipps University Marburg
    New P2 trial
    |
    Winrevair (sotatercept-csrk)
    7d
    SOTERIA: A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-038) (clinicaltrials.gov)
    P3, N=815, Recruiting, Merck Sharp & Dohme LLC | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Winrevair (sotatercept-csrk)
    7d
    A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-031/LIGHTRAY EXTENSION) (clinicaltrials.gov)
    P2, N=130, Active, not recruiting, Merck Sharp & Dohme LLC | Recruiting --> Active, not recruiting | Trial completion date: Sep 2027 --> Jun 2028 | Trial primary completion date: Sep 2027 --> Jun 2028
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    Winrevair (sotatercept-csrk)
    7d
    LIGHTRAY: A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (PAH) (MK-7962-024) (clinicaltrials.gov)
    P2, N=164, Completed, Merck Sharp & Dohme LLC | Active, not recruiting --> Completed
    Trial completion
    |
    Winrevair (sotatercept-csrk)
    2ms
    SOTERIA: A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-038) (clinicaltrials.gov)
    P3, N=815, Not yet recruiting, Merck Sharp & Dohme LLC
    New P3 trial
    |
    Winrevair (sotatercept-csrk)
    2ms
    Sotatercept (ACE-011) With Lenalidomide or Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov)
    P1, N=33, Active, not recruiting, Massachusetts General Hospital | Trial completion date: Jun 2025 --> Jun 2026 | Trial primary completion date: Dec 2024 --> Dec 2025
    Trial completion date • Trial primary completion date
    |
    lenalidomide • pomalidomide • Winrevair (sotatercept-csrk)
    2ms
    Sotatercept in Pulmonary Arterial Hypertension (clinicaltrials.gov)
    P4, N=27, Recruiting, University of Alberta | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Winrevair (sotatercept-csrk)
    2ms
    A Study of Sotatercept (MK-7962) in Healthy Females Administered as a Liquid Formulation in an Autoinjector Versus the Lyophilized Formulation (MK-7962-027) (clinicaltrials.gov)
    P1, N=146, Active, not recruiting, Merck Sharp & Dohme LLC | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Winrevair (sotatercept-csrk)
    3ms
    Right Ventricular Compensation With Sotatercept: A Prospective Single Arm Open Label Phase 4 Study to Evaluate the Effects of Sotatercept on Right Ventricular Function in Pulmonary Arterial Hypertension (RECOMPENSE) (clinicaltrials.gov)
    P4, N=20, Recruiting, Amsterdam UMC, location VUmc | Not yet recruiting --> Recruiting | Trial completion date: Oct 2026 --> May 2026 | Initiation date: Jan 2025 --> May 2025 | Trial primary completion date: Oct 2026 --> May 2026
    Enrollment open • Trial completion date • Trial initiation date • Trial primary completion date
    |
    Winrevair (sotatercept-csrk)
    4ms
    Sotatercept in Pulmonary Arterial Hypertension (clinicaltrials.gov)
    P4, N=27, Not yet recruiting, University of Alberta
    New P4 trial
    |
    Winrevair (sotatercept-csrk)
    4ms
    CADENCE: A Study of Sotatercept for the Treatment of Cpc-PH Due to HFpEF (MK-7962-007/A011-16) (clinicaltrials.gov)
    P2, N=150, Active, not recruiting, Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA | Trial completion date: Sep 2025 --> Dec 2025
    Trial completion date
    |
    Winrevair (sotatercept-csrk)